Nexalin Technology, Inc. Plans Q-Submission to FDA for Gen-2 SYNC

Nexalin Technology, Inc. announced its intention to submit a Q-Submission to the U.S. FDA concerning its Gen-2 SYNC system, which aims to enhance clinical trial design for treating Alzheimer’s disease, dementia, and mild cognitive impairment. This decision follows positive internal data and initial feedback from the FDA, marking a significant regulatory step forward for Nexalin's non-invasive neuromodulation therapy. Nexalin uses bioelectronic medical technology for non-invasive neurostimulation to target mental health disorders in the mid-brain.